TNDM
Tandem Diabetes Care Inc
15.70$
-1.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 51.6% | 52.6% | 50.6% | 49.2% | 65.7% | 44.3% | 49.5% | 47.7% | 46.1% | 42.3% | 44.7% | 43.1% | 44.0% | |
| 48.4% | 47.4% | 49.4% | 50.8% | 34.3% | 55.7% | 50.5% | 52.3% | 53.9% | 57.7% | 55.3% | 56.9% | 56.0% | |
| 22.6% | 21.6% | 24.1% | 22.2% | 14.1% | 18.5% | 53.5% | 20.0% | 19.2% | 15.9% | 18.6% | 18.4% | 17.9% | |
| 42.7% | 43.6% | 47.0% | 42.5% | 27.4% | 37.4% | 48.6% | 45.5% | 43.5% | 38.9% | 43.8% | 43.9% | 42.4% | |
| 65.3% | 65.2% | 71.1% | 64.7% | 41.5% | 55.9% | 102.1% | 73.8% | 61.9% | 54.8% | 62.4% | 62.3% | 60.1% | |
| -17.0% | -17.8% | -21.7% | -13.9% | -7.2% | -0.2% | -51.6% | -21.5% | -8.0% | 2.9% | -7.1% | -5.4% | -4.1% | |
| 2.6% | 0.9% | 1.0% | 0.8% | 0.5% | 0.7% | 0.6% | 1.1% | 0.8% | 0.7% | 0.7% | 1.0% | 0.8% | |
| -16.6% | -15.9% | -20.6% | -13.4% | -6.2% | 0.0% | -52.1% | -24.0% | -10.1% | 1.6% | -8.0% | -8.1% | -5.9% | |
| 1.2% | -0.7% | 1.7% | 0.5% | 0.2% | -0.3% | 3.6% | -2.2% | -1.6% | 1.8% | 0.2% | 0.2% | 0.2% | |
| -17.8% | -15.2% | -22.3% | -13.9% | -6.4% | 0.3% | -55.7% | -21.8% | -8.5% | -0.2% | -8.2% | -8.3% | -6.1% | |
| -12.2% | -13.0% | -17.8% | -10.7% | -4.6% | 2.2% | -49.7% | -21.1% | -7.5% | 3.9% | -5.6% | -5.4% | -3.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.